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misses the key ﬁ nding of our study: 
community-wide treatment is highly 
cost eﬀ ective in many settings, even 
when elimination is not reached, 
because of the significant averted 
morbidity, both in children and adults.1 
The ability of mass drug administration 
to eliminate schistosomiasis and soil-
transmitted helminthiasis has not 
yet been satisfactorily proven, and 
countries will need to make funding 
decisions without knowing whether 
elimination—or just control—will be 
achieved. To put these eﬀ orts against 
one another is unproductive and not 
based on evidence. 
When infected human populations—
whether preschool-aged children or 
adults—remain untreated, they act 
as a hidden reservoir and continue to 
drive reinfection. We have shown that 
expanded community-wide treatment 
against schistosomiasis and soil-
transmitted helminthiasis addresses 
this hidden reservoir, decreases overall 
disease transmission, and is highly cost 
eﬀ ective. Global guidelines should be 
re-examined to address this important 
ﬁ nding.
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Authors’ reply
We are delighted by the interest in 
our study of the cost-effectiveness 
of expanded community-wide 
treatment against schistosomiasis 
and soil-transmitted helminthiasis.1 
In response to the critique by 
Hugo Turner and colleagues, we oﬀ er 
the following points for consideration. 
First, the use of binary disability 
weights for schistosomiasis is 
conservative, standard practice, and 
used by the Global Burden of Diseases 
study,2 among others. Although we 
agree that better data is needed to 
inform disability as a function of 
schistosomiasis burden, we employed 
these conventional disability weights 
because such data are limited and 
we recognised disability even at low 
disease burden.3 Importantly, the use 
of a binary disability weight is in fact 
conservative with respect to cost-
effectiveness, since no treatment 
benefit is given unless an infection 
is cured. Indeed, recalculation with 
intensity-stratiﬁ ed disability weights 
reveals that community-wide 
treatment is even more cost eﬀ ective 
(table; methods are further detailed 
in the appendix).4,5 Second, concern 
is raised over our use of a constant 
relation between parasitic worm 
burden and egg production from one 
helminth species to another. We tested 
alternative species-specific values 
for this poorly measured p arameter 
and found that our results are highly 
robust (appendix). 
Taken together, the two method-
ological issues did not aﬀ ect our results 
or conclusions.
Turner and colleagues further 
speculate that community-wide 
treatment might not be necessary in 
regions that are highly endemic for only 
Trichuris trichiura and Ascaris lumbricoides 
in school-aged children, which provides 
a hypothetical epidemiological situation 
to illustrate their argument. In reality, 
hookworm and schistosomiasis—
with an age distribution that greatly 
affects adults—are frequently 
co-endemic with T trichiura and 
A lumbricoides.6,7 Furthermore, T trichiura 
and A lumbricoides do affect adult 
populations and are thus not conﬁ ned 
to school-aged children alone, as shown 
by our use of real-world, age-structured 
data from four diverse epidemiological 
settings in Côte d’Ivoire.1 Turner and 
colleagues miss another key message 
of the study: integration of mass drug 
administration (ie, giving albendazole 
with praziquantel) takes advantage 
of cost-efficiencies since most drugs 
are donated and the treatment cost 
is mostly for delivery. Integrated 
treatment should therefore almost 
always be considered in co-endemic 
settings, and integration in co-endemic 
settings should be considered in future 
studies of community-wide treatment 
with albendazole alone.8
We are disappointed with 
the unsupported assertion that 
community-wide treatment will 
only be beneficial when elimination 
is reached. This outcome has not 
been shown in empirical studies and 
Binary weight Stratiﬁ ed weights
School-aged children* 118 98
Community-wide† 167 145
DALY=disability-adjusted life year. A lower incremental cost-eﬀ ectiveness ratio is more cost eﬀ ective, and an 
intervention was considered highly cost eﬀ ective if the incremental cost-eﬀ ectiveness ratio was less than 
US$1521 per DALY. *Relative to no treatment. †Relative to treatment of school-aged children. 
Table: Incremental cost-eﬀ ectiveness ratio (US$ per DALY averted) of strategies for integrated 
mass drug administration targeting schistosomiasis and soil-transmitted helminthiasis using 
intensity-stratiﬁ ed disability weight for schistosomiasis
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